Ocular Therapeutix enrolls first patient in SOL-X AXPAXLI wet AMD extension trial

• Ocular Therapeutix enrolled first patient in April 2026 in SOL-X, a long-term extension trial of AXPAXLI for wet age-related macular degeneration.
• Trial follows previously presented results from Phase 3 SOL-1, which supported AXPAXLI’s durability and sustained disease control without detailing metrics.
• SOL-X will track long-term safety, with focus on whether continuous treatment can support better long-term visual outcomes while reducing treatment burden.
• Enrollment open to patients completing two-year follow-up in SOL-1 or SOL-R, with up to three additional years of treatment and follow-up.
• Program positions AXPAXLI for broader uptake if longer-term data support improved retention and a larger commercial opportunity in wet AMD.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ocular Therapeutix Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604290700PRIMZONEFULLFEED9709153) on April 29, 2026, and is solely responsible for the information contained therein.